clodronic acid has been researched along with Bone Cancer in 207 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (14.01) | 18.7374 |
| 1990's | 82 (39.61) | 18.2507 |
| 2000's | 71 (34.30) | 29.6817 |
| 2010's | 23 (11.11) | 24.3611 |
| 2020's | 2 (0.97) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Goodwin, A; O'Carrigan, B; Pavlakis, N; Stockler, MR; Willson, ML; Wong, MH | 1 |
| Bianchi, G; Cantarini, L; Dalle Carbonare, L; Frediani, B; Giusti, A; Malavolta, N; Molfetta, L; Saviola, G | 1 |
| Zheng, Y; Zhou, Z; Zhu, J | 1 |
| Chen, H; Chen, W; Duan, F; Jin, H; Li, C; Liu, Q; Mo, L; Wang, F; Weng, Z; Yu, Z | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Gravis, G; Salem, N; Walz, J | 1 |
| Cho, SW; Daignault-Newton, S; Entezami, P; Jones, JD; Kim, YW; Koh, AJ; McCauley, LK; Park, SI; Pienta, KJ; Roca, H; Soki, FN | 1 |
| Aapro, M; Albert, US; Bergh, J; Body, JJ; Cameron, D; Clézardin, P; Coleman, RE; Conte, PF; Cortes, J; Costa, L; Di Leo, A; Diel, I; Dodwell, D; Ejlertsen, B; Gnant, M; Gray, R; Hadji, P; Harbeck, N; Holen, I; Kaufmann, M; Markopoulos, C; Martin, M; Powles, TJ; Santini, D; Smith, I; Thurlimann, B; Untch, M; Wilson, C | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Bastert, G; Diel, IJ; Gollan, C; Jaschke, A; Schuetz, F; Sohn, C; Solomayer, EF | 1 |
| Fotovati, A; Hiraoka, K; Hosoi, F; Iguchi, H; Kimura, YN; Kuwano, M; Nagata, K; Ono, M; Osada, H; Shoda, T; Watari, K; Zenmyo, M | 1 |
| Bartl, R | 1 |
| Coleman, RE | 4 |
| Cruz, LS; Fonseca, M; Machado, M; Tannus, G | 1 |
| Dearnaley, DP; Mason, MD; Parmar, MK; Sanders, K; Sydes, MR | 1 |
| Kanis, J; McCloskey, E; Paterson, A; Powles, T; Tähtelä, R | 1 |
| Cordes, T; di Liberto, A; Friedrich, M; Salehin, D; Tauchert, S; Thill, M | 1 |
| Habib, EE; Sabry, NA | 1 |
| Lipton, A; Saad, F | 1 |
| Brufsky, AM | 1 |
| Deuber, HJ; Theiss, F | 1 |
| Ahrens, H; Gosheger, G; Gouin, F; Hardes, J; Henrichs, M; Lanvers-Kaminzky, C; Streitbuerger, A | 1 |
| Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, F; Rudin, C; Szubert, AJ | 1 |
| Rajkumar, SV | 1 |
| Choi, HJ; Fan, D; Fidler, IJ; He, J; Kim, JS; Kim, SJ; Kim, SW; Langley, RR; Maya, M; Papadopoulos, J | 1 |
| Berenson, J; Dimopoulos, MA; Terpos, E | 1 |
| Cunio Machado Fonseca, M; Etto, H; Machado, M; Santoni, N; Schiola, A; Tannus Branco de Araújo, G | 1 |
| Chlebowski, RT; Col, N | 1 |
| Morgans, AK; Smith, MR | 1 |
| Mundy, GR | 1 |
| Ashley, S; Atula, S; Kanis, JA; Legault, S; Männistö, E; McCloskey, E; Nevalainen, J; Nevantaus, A; Ottestad, L; Pajunen, M; Paterson, S; Powles, T; Pylkkänen, L; Rosenqvist, K; Smith, I; Suovuori, A; Tidy, A | 1 |
| Gralow, JR | 1 |
| Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K | 1 |
| Cook, R; Major, PP | 1 |
| Horváth, Z | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Fujitani, K; Hirao, M; Kida, H; Tsujinaka, T; Yoshioka, S | 1 |
| Ashcroft, AJ; Davies, FE; Morgan, GJ | 1 |
| Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW | 1 |
| Saad, F | 1 |
| Bankhead, C | 2 |
| Dearnaley, DP; Mason, MD; Moffat, LE; Naylor, SL; Parmar, MK; Powell, CS; Robinson, AC; Stott, M; Sydes, MR; Thompson, PM | 1 |
| Chow, E; Clemons, M; Enright, K | 1 |
| Smith, MR | 1 |
| Lipton, A | 3 |
| Berenson, J; Hirschberg, R | 1 |
| Coombes, C; Dhillon, T; Palmieri, C; Vigushin, D | 1 |
| Deangelis, C; Einarson, TR; Iscoe, N; Romanus, D; Shear, N | 1 |
| Coleman, R; Conte, P | 1 |
| Campagnari, JC; Hering, F; Rodrigues, P | 1 |
| Blomqvist, C; Saarto, T; Vehmanen, L; Virkkunen, P | 1 |
| Dando, TM; Wiseman, LR | 1 |
| Kamby, C; Kristensen, B; Pedersen, L | 1 |
| Khuri, F; Saba, N | 1 |
| Altan, A; Demir, C; Ozyuvaci, E | 1 |
| Blomqvist, C; Elomaa, I; Leppä, S; Saarto, T; Vehmanen, L | 1 |
| Gralow, J | 1 |
| Clemons, M; Verma, S | 1 |
| Parker, CC | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| Dahut, WL; Gulley, J | 1 |
| Ashley, S; Kanis, J; McCloskey, E; Ottestad, L; Paterson, A; Powles, T; Scheffler, B; Schein, P; Smith, I; Tidy, A | 1 |
| Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G | 1 |
| Clézardin, P; Daubiné, F; Gasser, J; Green, J; Le Gall, C | 1 |
| Ha, TC; Li, H | 1 |
| Pritchard, KI | 1 |
| Body, JJ; Brown, JE; Cameron, DA; Coleman, RE; Dewar, JA; Harnett, AN; McCloskey, EV; Purohit, OP; Ruutu, M; Tähtelä, R | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Blomqvist, C; Elomaa, I; Gröhn, P; Holmström, T; Kairento, AL; Lamberg-Allardt, C; Porkka, L; Selander, K | 1 |
| Briançon, D; Chapuy, MC; Charhon, S; Delmas, P; Meunier, PJ; Vignon, E | 1 |
| Canfield, RE; Hyman, GA; Siris, ES | 1 |
| Chantraine, A; Donath, A; Jung, A; Kitler, ME; Mermillod, B; Turnill, D; van Ouwenaller, C | 1 |
| Blomqvist, C; Elomaa, I; Leirisalo, M; Markkula, R; Repo, H | 1 |
| Chantraine, A; Donath, A; Jung, A; van Ouwenaller, C | 1 |
| Blomqvist, C; Elomaa, I; Holmström, T; Laine, H; Porkka, L | 1 |
| Delmas, PD; Meunier, PJ | 1 |
| Alexandre, CM; Chapuy, MC; Meunier, PJ; Vignon, EP | 1 |
| Baquiran, DC; Bilezikian, JP; Canfield, RE; Jacobs, TP; Shane, E; Siris, ES | 1 |
| Chantraine, A; Donath, A; Jung, A; Rosini, S; van Ouwenaller, C | 1 |
| Charhon, S; Cheix, F; Meunier, PJ; Vauzelle, JL; Vergnon, JM | 1 |
| Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C | 1 |
| Fleisch, H; Jung, A | 1 |
| Jung, A | 1 |
| Vorreuther, R | 1 |
| Kirstein, A; Voigtmann, R | 1 |
| Goa, KL; Plosker, GL | 1 |
| Kylmälä, T; Lindholm, TS; Seppänen, J; Tammela, TL | 1 |
| Cresswell, SM; English, PJ; Hall, RR; Marsh, MM; Roberts, JT | 1 |
| Anthony, C; Coleman, RE; Kanis, JA; Purohit, OP; Radstone, CR | 1 |
| Ralston, SH; Reed, NS; Robertson, AG | 1 |
| Elomaa, I; Kylmälä, T; Risteli, J; Risteli, L; Tammela, T; Taube, T | 1 |
| Koyano, H; Schimizu, T; Shishiba, Y | 1 |
| Houghton, F; Huss, H; Kanis, JA; McCloskey, E; O'Rourke, N | 1 |
| Elomaa, I; Kylmälä, T; Lamberg-Allardt, C; Tammela, TL; Taube, T | 1 |
| Dearnaley, DP; Glaholm, J; Mason, MD | 1 |
| Kiełbiński, M | 1 |
| Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ | 3 |
| Beghé, F; Luzzani, M | 1 |
| Baumgartner, G; Janisch, S; Ogris, E; Pecherstorfer, M; Schilling, T; Woloszczuk, W; Ziegler, R | 1 |
| Beneton, MN; Blomqvist, C; Elomaa, I; Kanis, JA; Taube, T | 1 |
| Krempien, B; Manegold, C | 1 |
| Kanis, JA | 2 |
| Blinov, NN; Moiseenko, VM | 1 |
| Castrén-Kortekangas, P; Kylmälä, T; Seppänen, J; Tammela, TL; Ylitalo, P | 1 |
| Ashley, S; Kanis, JA; McCloskey, EV; Paterson, AH; Powles, T | 1 |
| Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J | 1 |
| Body, JJ; Coleman, RE; Piccart, M | 1 |
| Strang, P | 1 |
| Blomqvist, C; Elomaa, I | 1 |
| Paterson, AH | 2 |
| Brasher, P; Bruera, E; Ernst, DS; Hagen, N; MacDonald, RN; Paterson, AH | 1 |
| Del Campo, MT; Jariego, C; Martínez, ME; Pastrana, P; Sánchez-Cabezudo, MJ | 1 |
| Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S | 1 |
| Elomaa, I; Kylmälä, T; Risteli, J; Risteli, L; Tammela, TL; Taube, T | 1 |
| Aaron, JE; Alcover, J; Carretero, P; Fernández-Conde, M; Ordi, J | 1 |
| Adami, S | 1 |
| Heidenreich, A | 1 |
| Bloomfield, DJ | 1 |
| Kylmälä, T | 1 |
| Bastert, G; Costa, SD; Diel, IJ; Goerner, R; Gollan, C; Kaufmann, M; Solomayer, EF; Wallwiener, D | 1 |
| Mundy, GR; Yoneda, T | 1 |
| Acito, L; Bracci, R; Carle, F; Cellerino, R; Di Furia, L; Ferretti, B; Nortilli, R; Pancotti, A; Piga, A; Sandri, P | 1 |
| Englund, G; Larsson, B; Larsson, L; Magnusson, P; Selin-Sjögren, L; Strang, P | 1 |
| Derrane, M | 1 |
| Diel, IJ | 3 |
| Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD | 1 |
| Meli, M; Rausa, L | 1 |
| Melnychuk, D; Panasci, LC; Sandor, V | 1 |
| Blinov, NN; Konstantinova, MM; Moiseenko, VM; Semiglazov, VV; Trishkina, EA | 1 |
| Ashley, S; Kanis, JA; McCloskey, EV; Paterson, AH; Powles, T; Spector, T | 1 |
| Elo, HA; Holli, K; Juhakoski, A; Liukko-Sipi, S; Mönkkönen, J; Ylitalo, P; Ylitalo, R | 1 |
| Bychenkov, OA; Larionova, NA; Moc'kin, VG; Poliakov, PIu | 1 |
| Ejlertsen, B; Groenvold, M; Hein, S; Kristensen, B; Loft, H; Mouridsen, HT | 1 |
| Berthaud, P; Jadaud, E; Lortholary, A | 1 |
| Açikgöz, N; Akbulut, H; Arican, A; Cakir, M; Demirkazik, A; Içli, F; Samur, M; Sencan, O | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Badzio, A; Jassem, J; Jereczek-Fossa, B; Serkies, K | 1 |
| Ahlström, H; Andréasson, I; Aström, G; Bergh, J; Ciray, I; Edekling, T; Hansen, J | 1 |
| Brion, N; Clerc, D; Paule, B | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Bastert, G; Diel, IJ; Solomayer, EF | 2 |
| Engelmann, UH; Heidenreich, A; Hofmann, R | 1 |
| Blomqvist, C; Elomaa, I; Saarto, T; Virkkunen, P | 1 |
| Choong, PF; Fisher, JL; Mackie, PS; Zhou, H | 1 |
| Johnson, IS | 1 |
| Boos, J; Eckervogt, V; Sonnemann, J; Truckenbrod, B; van Valen, F; Winkelmann, W | 1 |
| Jones, J | 1 |
| Assadourian, S; Barbet, N; Bessa, E; Beuzeboc, P; Frenay, M; Mauriac, L; Misset, JL; Monnier, A; Pion, JM; Switsers, O; Tubiana-Hulin, M | 1 |
| Berneman, ZN; Buytaert, PM; Tjalma, WA | 1 |
| Coleman, RE; Heatley, S; Herling, C; Jagdev, SP; Purohit, P | 1 |
| Hamdy, NA; Pelger, RC; Soerdjbalie-Maikoe, V | 1 |
| Mykała-Cieśla, J; Stajszczyk, M | 1 |
| Härkönen, PL; Lakkakorpi, PT; Väänänen, HK; Virtanen, SS | 1 |
| Adam, Z | 1 |
| Wiffen, PJ; Wong, R | 1 |
| Engelking, R; Klotz, T; Vorreuther, R | 1 |
| Ala-Opas, M; Elomaa, I; Jauhiainen, K; Kylmälä, T; Ottelin, J; Roos, L; Ruutu, M; Seppänen, J; Tammela, T; Viitanen, J | 1 |
| Henning, HV; Warneke, G | 1 |
| Bandmann, U; Eriksson, M; Glas, U; Hansen, J; Pfeiffer, P; Rotstein, S; Söderqvist, J; Strid, S | 1 |
| Benvenuti, F; Colombi, L; Gemelli, MT; Ludovici, M; Neri, B; Pacini, P; Sambataro, S | 1 |
| Geldof, AA; Newling, DW; Rao, BR; Sun, YC | 1 |
| Brasher, P; Bruera, E; Ernst, DS; Jensen, J; MacDonald, RN; Paterson, AH | 1 |
| Conti, F; Francini, G; Gennari, C; Gonnelli, S; Paffetti, P; Petrioli, R | 1 |
| Ashley, S; Ernst, DS; Kanis, JA; McCloskey, EV; Paterson, AH; Powles, TJ | 1 |
| Biermann, WA; Cantor, RI; Fellin, FM; Hopkins, L; Jakobowski, J; Newbold, RC | 1 |
| Powles, T | 1 |
| Conte, N; Da Rin, G; Di Virgilio, R; Foscolo, G; Legovini, P; Pavan, P; Roiter, I | 1 |
| Beghé, F; Biagi, R; Camera, P; Guaraldi, M; Marri, S; Martoni, A; Pannuti, F | 1 |
| Beuzeboc, P; Pouillart, P | 1 |
| Burki, F | 1 |
| Botturi, M; Tosi, G; Zanni, D | 1 |
| Caulin, F | 1 |
| Beghè, F; Gottlieb, A; Luzzani, M; Nobile, MT; Rissotto, R; Rosso, R; Vidili, MG | 1 |
| Warrell, RP | 2 |
| Elomaa, I; Kärkkäinen, S; Nurmi, AK; Pentikäinen, PJ | 1 |
| Adami, S; Mian, M | 1 |
| Adami, S; Bianchi, G; Dorizzi, R; Guarrera, G; Lo Cascio, V; Mobilio, G; Rosini, S; Salvagno, G | 1 |
| Coleman, RE; Rubens, RD | 1 |
| Bijvoet, OL; Cleton, FJ; Elte, JW; Sleeboom, HP; van Oosterom, AT | 1 |
| Ascari, E; Attardo-Parrinello, G; Crema, F; Fiorentini, ML; Merlini, G; Pavesi, F | 1 |
| Blomqvist, C; Borgström, GH; Elomaa, I; Lamberg-Allardt, C; Porkka, L | 1 |
| Canfield, RE; Jacobs, TP; Siris, ES | 1 |
| Blomqvist, C; Borgström, GH; Elomaa, I; Holmström, T; Lamberg-Allardt, C; Porkka, L; Taube, T | 1 |
| Caberlotto, L; Conte, N; Di Virgilio, R; Roiter, I | 1 |
| Beard, DJ; Douglas, DL; Kanis, JA; Neal, FE; Paterson, AD; Percival, RC; Russell, RG; Yates, AJ | 1 |
| Kanis, JA; Percival, RC; Watson, ME; Williams, JL | 1 |
64 review(s) available for clodronic acid and Bone Cancer
| Article | Year |
|---|---|
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Bisphosphonates and other bone agents for breast cancer.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Clodronate in the management of different musculoskeletal conditions.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Humans; Muscle Neoplasms; Musculoskeletal Diseases; Orthopedic Procedures; Osteoarthritis; Osteoporosis | 2018 |
Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Disease-Free Survival; Female; Humans; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic | 2013 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
[Metastatic hormone-sensitive prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Combined Modality Therapy; Docetaxel; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Taxoids | 2015 |
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Consensus; Diphosphonates; Europe; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Surveys and Questionnaires; Zoledronic Acid | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Male; Pamidronate; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2009 |
Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.
Topics: Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Peptides; Prognosis; Prostatic Neoplasms; RANK Ligand; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2010 |
The evolving role of bone-conserving therapy in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Survival Analysis; Zoledronic Acid | 2010 |
[Bisphosphonates in adjuvant therapy of breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Drug Approval; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Pamidronate; Survival Rate; Zoledronic Acid | 2010 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2011 |
Bisphosphonates and breast cancer incidence and recurrence.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Incidence; Zoledronic Acid | 2011 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid | 2012 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Forecasting; Humans; Nitriles; Osteoporosis; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2002 |
[The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Female; Humans; Incidence; Survival Analysis; Treatment Outcome | 2002 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
Topics: Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Chemokines; Clinical Trials as Topic; Clodronic Acid; Cytokines; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteolysis; Patient Selection; Treatment Outcome; Zoledronic Acid | 2003 |
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.
Topics: Analgesics, Non-Narcotic; Antimetabolites; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2003 |
Bisphosphonate therapy in the oncology setting.
Topics: Administration, Oral; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid | 2003 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Bisphosphonates in the treatment of skeletal metastases.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2004 |
Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Disease Management; Humans | 2004 |
[Diphosphonates in solid malignant tumors].
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms | 2005 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid | 2005 |
Should oral bisphosphonates be standard of care in women with early breast cancer?
Topics: Antimetabolites; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Pamidronate; Prognosis; Survival | 2005 |
The role of bisphosphonates in the treatment of prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Clinical Trials, Phase III as Topic; Clodronic Acid; Diphosphonates; Forecasting; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Clodronate in the prevention and treatment of skeletal metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Dose-Response Relationship, Drug; Female; Humans; Male; Morbidity; Prostatic Neoplasms; Risk Factors | 2005 |
Meta-analysis of clodronate and breast cancer survival.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcinosis; Clinical Trials as Topic; Clodronic Acid; Dose-Response Relationship, Drug; Half-Life; Humans; Hydroxyproline; Hypercalcemia; Infusions, Intravenous; Metabolic Clearance Rate; Neoplasms; Osteitis Deformans; Osteoporosis; Tissue Distribution | 1994 |
[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis].
Topics: Bone Neoplasms; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasms; Osteolysis; Osteosclerosis; Pamidronate | 1994 |
Bone and cancer: pathophysiology and treatment of metastases.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Pain; Pamidronate; Parathyroid Hormone | 1995 |
[Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology].
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Humans; Osteogenesis | 1996 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Pain; Pamidronate; Structure-Activity Relationship | 1996 |
Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article.
Topics: Analgesia; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Osteoclasts; Pain; Pamidronate | 1996 |
Rationale for the use of bisphosphonates in breast cancer.
Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphonates; Fractures, Spontaneous; Humans; Hypercalcemia; Osteoclasts; Pain; Pamidronate; Quality of Life | 1996 |
Bisphosphonate therapy in metastatic breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans; Pamidronate | 1996 |
Should bisphosphonates be standard therapy for bone pain?
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Hypercalcemia; Male; Pain | 1997 |
Bisphosphonates and breast carcinoma.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Humans; Pain; Pamidronate; Treatment Outcome | 1997 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Male; Neoplasm Invasiveness; Osteoclasts; Pain; Prostatic Neoplasms | 1997 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence-Based Medicine; Female; Humans; Male; Multiple Myeloma; Pain; Pamidronate; Practice Guidelines as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1998 |
Aredia: the once-monthly infusion for the treatment of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Multiple Myeloma; Osteoclasts; Pamidronate; Randomized Controlled Trials as Topic | 1998 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease Models, Animal; Female; Humans; Mammary Neoplasms, Experimental; Pamidronate; Rats | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate | 1998 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Male; Multiple Myeloma; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Pamidronate | 2000 |
Bisphosphonates in the prevention of bone metastases: current evidence.
Topics: Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans; Survival Analysis | 2001 |
Adjuvant bisphosphonate therapy: the future.
Topics: Bone Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Humans | 2001 |
Strategies for management of prostate cancer-related bone pain.
Topics: Analgesics; Animals; Bone Neoplasms; Clodronic Acid; Humans; Male; Pain; Pain Management; Prostatic Neoplasms; Radioisotopes | 2001 |
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Hypercalcemia; Incidence; Pain; Pamidronate; Patient Selection; Survival Analysis; Treatment Outcome | 2000 |
[Bisphosphonates in the treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2001 |
Bisphosphonates for the relief of pain secondary to bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Pain; Pamidronate; Randomized Controlled Trials as Topic | 2002 |
[Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism].
Topics: Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Osteoporosis; Structure-Activity Relationship | 1992 |
Treatment of skeletal disease in breast cancer with clodronate.
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Combined Modality Therapy; Double-Blind Method; Fractures, Spontaneous; Humans; Hypercalcemia; Incidence; Injections, Intravenous; Osteolysis; Pain; Palliative Care; Prospective Studies; Spinal Fractures; Treatment Outcome | 1991 |
An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone.
Topics: Ambulatory Care; Analgesics; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Costs and Cost Analysis; Epidural Space; Fractures, Spontaneous; Hospitalization; Hospitals, University; Humans; Hypercalcemia; Incidence; Length of Stay; Osteolysis; Outpatient Clinics, Hospital; Pain; Palliative Care; Philadelphia; Radiotherapy; Retrospective Studies; Spinal Neoplasms | 1991 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hypercalcemia; Neoplasm Proteins; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Transforming Growth Factors | 1990 |
Bone metastases and breast cancer.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Binding Proteins; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Humans; Lymphokines; Osteocalcin; Osteogenesis; Pamidronate; Peptides; Prostaglandin Antagonists; Prostaglandins; Tomography, X-Ray Computed; Transforming Growth Factors | 1985 |
Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diagnosis, Differential; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Osteolysis | 1986 |
69 trial(s) available for clodronic acid and Bone Cancer
| Article | Year |
|---|---|
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases.
Topics: Aged; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2013 |
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Radiotherapy | 2008 |
Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
Topics: Administration, Oral; Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Double-Blind Method; Female; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Peptide Fragments; Procollagen | 2010 |
Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Young Adult; Zoledronic Acid | 2011 |
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Research Design; Treatment Outcome; United Kingdom; Zoledronic Acid | 2010 |
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
Topics: Administration, Oral; Antimetabolites; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2002 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Regression Analysis; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Topics: Administration, Oral; Aged; Analgesics, Non-Narcotic; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Digestive System; Diphosphonates; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Odds Ratio; Pain; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid | 2003 |
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
Topics: Aged; Antimetabolites; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Follow-Up Studies; History, 17th Century; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Receptors, Estrogen; Survival Analysis | 2004 |
[The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
Topics: Administration, Oral; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pain, Intractable; Prostatic Neoplasms; Treatment Outcome | 2005 |
Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Topics: Antimetabolites; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Disease-Free Survival; Female; Finland; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Survival Rate | 2005 |
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Staging; Placebos; Random Allocation; Recurrence; Survival Analysis | 2006 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease Progression; Drug Resistance; Female; Humans; Imidazoles; Middle Aged; Pain; Palliative Care; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Peptide Fragments; Placebos; Predictive Value of Tests; Procollagen; Prostatic Neoplasms; Sensitivity and Specificity; Treatment Outcome | 2007 |
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrocarbons, Chlorinated; Methylene Chloride; Middle Aged; Osteolysis; Random Allocation; Time Factors | 1983 |
[Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author's transl)].
Topics: Adult; Aged; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Male; Middle Aged | 1982 |
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Double-Blind Method; Female; Humans; Hydroxyproline; Hypercalcemia; Middle Aged; Osteoclasts | 1983 |
Use of dichloromethylene diphosphonate in metastatic bone disease.
Topics: Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Double-Blind Method; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Random Allocation | 1983 |
Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Chemotaxis, Leukocyte; Clodronic Acid; Diphosphonates; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Lymphocyte Activation; Lymphocytes; Middle Aged; Placebos | 1983 |
[Dichloromethylene diphosphonate in the treatment of lytic bone metastases].
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Osteolysis | 1984 |
Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate.
Topics: Aged; Bone Neoplasms; Clodronic Acid; Humans; Male; Pain; Palliative Care; Pilot Projects; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1993 |
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Double-Blind Method; Humans; Hypercalcemia; Pamidronate; Treatment Outcome | 1995 |
Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Analgesics; Bone Neoplasms; Clodronic Acid; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Pain Measurement | 1995 |
Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Clodronic Acid; Collagen; Estramustine; Humans; Male; Middle Aged; Pain; Palliative Care; Peptide Fragments; Procollagen; Prostatic Neoplasms | 1993 |
Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Clodronic Acid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteolysis; Patient Compliance | 1995 |
The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Bone Resorption; Clodronic Acid; Double-Blind Method; Humans; Male; Middle Aged; Osteogenesis; Osteomalacia; Prostatic Neoplasms | 1994 |
[Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Clodronic Acid; Double-Blind Method; Female; Humans; Middle Aged; Osteolysis | 1993 |
Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study.
Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Cell Count; Clodronic Acid; Female; Humans; Hydroxyproline; Middle Aged; Osteoclasts | 1993 |
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Clodronic Acid; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Middle Aged | 1993 |
Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analysis of Variance; Antineoplastic Agents, Hormonal; Biological Availability; Bone Neoplasms; Carcinoma; Clodronic Acid; Drug Synergism; Drug Therapy, Combination; Estramustine; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1996 |
Clodronate decreases the frequency of skeletal metastases in women with breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; Survival Rate | 1996 |
Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Hydroxyproline; Hypercalcemia; Male; Middle Aged; Pamidronate; Parathyroid Hormone; Peptides | 1997 |
A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analysis of Variance; Bone Neoplasms; Chi-Square Distribution; Clodronic Acid; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pain Measurement; Pain, Intractable; Treatment Outcome | 1997 |
Effect of clodronate on calcidiol serum levels in women with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Calcifediol; Calcium; Clodronic Acid; Female; Humans; Middle Aged; Parathyroid Hormone | 1997 |
Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Collagen; Double-Blind Method; Humans; Injections, Intravenous; Male; Middle Aged; Pain; Peptide Fragments; Procollagen; Prospective Studies; Prostatic Neoplasms | 1997 |
Skeletal response to clodronate in prostate cancer with bone metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Bone and Bones; Bone Matrix; Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Clodronic Acid; Disease Progression; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Injections, Intravenous; Male; Middle Aged; Orchiectomy; Osteoblasts; Osteoclasts; Palliative Care; Prostatic Neoplasms; Quality of Life | 1997 |
[Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
Topics: Analgesics, Non-Narcotic; Antibiotics, Antineoplastic; Bone Neoplasms; Clodronic Acid; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms | 1997 |
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Humans; Incidence; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Analysis | 1998 |
A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Double-Blind Method; Humans; Infant, Newborn; Middle Aged; Neoplasms; Placebos | 1998 |
Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analgesics, Non-Narcotic; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Clodronic Acid; Collagen; Collagen Type I; Double-Blind Method; Humans; Isoenzymes; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteocalcin; Pain, Intractable; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms | 1998 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease Models, Animal; Female; Humans; Mammary Neoplasms, Experimental; Pamidronate; Rats | 1998 |
[Randomized trial of two administration schedule of bonephos (Clodronate) in patients with painful bone metastasis].
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Bone Resorption; Clodronic Acid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Pain, Intractable; Treatment Outcome | 1998 |
A high incidence of vertebral fracture in women with breast cancer.
Topics: Administration, Oral; Age Factors; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Cohort Studies; Double-Blind Method; Female; Humans; Incidence; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Osteoporosis; Spinal Fractures; Tamoxifen | 1999 |
Comparison of pharmacokinetics of clodronate after single and repeated doses.
Topics: Adult; Aged; Bone Neoplasms; Clodronic Acid; Cross-Over Studies; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypercalcemia; Male; Middle Aged; Reference Values | 1999 |
[An experience with combined therapy of radiation and Bonephos for osteolytic metastases of breast cancer].
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Humans; Pain, Intractable; Radiotherapy, Adjuvant; Treatment Outcome | 1999 |
Oral clodronate in breast cancer patients with bone metastases: a randomized study.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Disease Progression; Female; Humans; Middle Aged; Prospective Studies; Quality of Life; Survival Analysis | 1999 |
The effect of two different doses of oral clodronate on pain in patients with bone metastases.
Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Female; Humans; Male; Middle Aged; Pain; Palliative Care | 1999 |
Evaluation of new sclerotic bone metastases in breast cancer patients during treatment.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diagnosis, Differential; Disease Progression; Female; Humans; Middle Aged; Osteosclerosis; Radionuclide Imaging | 2000 |
The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Topics: Aged; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Humans; Karnofsky Performance Status; Male; Pain; Pain Measurement; Palliative Care; Prospective Studies; Prostatic Neoplasms; Time Factors | 2001 |
Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
Topics: Adult; Aged; Antimetabolites; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Survival Rate | 2001 |
[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Double-Blind Method; Female; Hormones; Humans; Middle Aged; Pain; Pain Measurement | 2001 |
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Bone Neoplasms; Bone Resorption; Clodronic Acid; Collagen; Diphosphonates; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pain; Pamidronate | 2001 |
[Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
Topics: Aged; Bone Neoplasms; Carcinoma; Clodronic Acid; Combined Modality Therapy; Humans; Male; Palliative Care; Pilot Projects; Prospective Studies; Prostatic Neoplasms | 1992 |
Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.
Topics: Administration, Oral; Aged; Analgesics; Bone Neoplasms; Calcium; Clodronic Acid; Estramustine; Humans; Male; Pain; Prostatic Neoplasms | 1992 |
Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Blood Proteins; Bone Neoplasms; Breast Neoplasms; Calcium; Clodronic Acid; Double-Blind Method; Female; Fluid Therapy; Humans; Hydroxyproline; Hypercalcemia; Hypocalcemia; Infusions, Intravenous; Middle Aged; Placebos; Prospective Studies | 1992 |
Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases.
Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Clodronic Acid; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Middle Aged; Osteocalcin; Pain; Pilot Projects | 1992 |
A double-blind, crossover trial of intravenous clodronate in metastatic bone pain.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Clodronic Acid; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pain; Pain Measurement | 1992 |
Treatment of bone metastases with dichloromethylene bisphosphonate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium; Chemotherapy, Adjuvant; Clodronic Acid; Drug Administration Schedule; Female; Humans; Hypercalcemia; Male | 1992 |
Treatment of skeletal disease in breast cancer with clodronate.
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Combined Modality Therapy; Double-Blind Method; Fractures, Spontaneous; Humans; Hypercalcemia; Incidence; Injections, Intravenous; Osteolysis; Pain; Palliative Care; Prospective Studies; Spinal Fractures; Treatment Outcome | 1991 |
Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Neoplasms; Clodronic Acid; Female; Humans; Male; Middle Aged; Osteocalcin; Osteolysis; Parathyroid Hormone | 1991 |
Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Middle Aged | 1991 |
New French studies of clodronate in cancer-induced osteolysis.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Combined Modality Therapy; Double-Blind Method; Female; France; Hormones; Humans; Osteolysis | 1991 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hypercalcemia; Neoplasm Proteins; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Transforming Growth Factors | 1990 |
Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Clodronic Acid; Diphosphonates; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intramuscular; Male; Multicenter Studies as Topic; Pain; Prostatic Neoplasms; Random Allocation | 1989 |
Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Hydroxyproline; Male; Middle Aged; Pain | 1987 |
Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Placebos; Vitamin D | 1987 |
Dichloromethylene diphosphonate action in hematologic and other malignancies.
Topics: Administration, Oral; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Hydroxyproline; Hypercalcemia; Infusions, Intravenous; Leukemia, Lymphoid; Male; Multiple Myeloma; Neoplasms; Pain | 1987 |
Clodronate for osteolytic metastases due to breast cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Middle Aged; Osteolysis | 1988 |
77 other study(ies) available for clodronic acid and Bone Cancer
| Article | Year |
|---|---|
Bone marrow macrophages support prostate cancer growth in bone.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Bone Regeneration; Carcinogenesis; Cell Growth Processes; Cell Line, Tumor; Clodronic Acid; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Prostatic Neoplasms; Receptor, Macrophage Colony-Stimulating Factor; Tumor Burden | 2015 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Disease Models, Animal; Female; Humans; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; Monocytes; Muscle Neoplasms; Neoplasm Invasiveness; Pyrans; Spiro Compounds | 2008 |
[Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2009 |
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Follow-Up Studies; Humans; Male; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases.
Topics: Acid Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Female; Humans; Isoenzymes; Palliative Care; Tartrate-Resistant Acid Phosphatase | 2009 |
Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chondrosarcoma; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Formazans; Humans; Imidazoles; Male; Tetrazolium Salts; Zoledronic Acid | 2011 |
Zoledronic acid in myeloma: MRC Myeloma IX.
Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.
Topics: Animals; Bone Neoplasms; Carcinoma; Cell Communication; Cell Line, Tumor; Clodronic Acid; Humans; Interleukin-6; Liposomes; Macrophages; Male; Mice; Mice, Nude; Osteoclasts; Prostatic Neoplasms; RNA, Small Interfering; Tumor Burden; Tumor Necrosis Factor-alpha | 2011 |
Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil.
Topics: Bone Neoplasms; Brazil; Clodronic Acid; Cost-Benefit Analysis; Diphosphonates; Economics, Pharmaceutical; Financing, Government; Humans; Imidazoles; Insurance, Health, Reimbursement; Private Sector; Zoledronic Acid | 2011 |
Bisphosphonates and tumor burden.
Topics: Administration, Oral; Animals; Antimetabolites; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Randomized Controlled Trials as Topic | 2002 |
Bisphosphonates as adjuvant treatment for breast cancer.
Topics: Administration, Oral; Antimetabolites; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Humans; Randomized Controlled Trials as Topic | 2002 |
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperesthesia; Imidazoles; Models, Animal; Neoplasm Transplantation; Observer Variation; Pain; Pain Measurement; Pain Threshold; Pamidronate; Radiography; Rats; Rats, Sprague-Dawley; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Tibia; Touch; Treatment Outcome; Zoledronic Acid | 2002 |
[A patient with gastric cancer complicated with severe DIC and multiple bone metastasis showing a high response to combination of TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clodronic Acid; Disseminated Intravascular Coagulation; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid | 2003 |
Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Extremities; Female; Humans; Middle Aged; Ontario; Palliative Care; Pamidronate; Radiotherapy, Adjuvant; Retrospective Studies; Spine; Treatment Outcome | 2004 |
Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice.
Topics: Antimetabolites; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Humans; Hypocalcemia; Infusions, Intravenous | 2004 |
Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.
Topics: Antimetabolites; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Chi-Square Distribution; Clodronic Acid; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Middle Aged; Pamidronate; Statistics, Nonparametric | 2004 |
Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Palliative Care; Prospective Studies; Prostatic Neoplasms; Time Factors | 2004 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Imidazoles; Luciferases; Mammary Neoplasms, Experimental; Mice; Osteolysis; Research Design; Zoledronic Acid | 2007 |
Bisphosphonates: are they standard of care for the treatment of breast cancer?
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Randomized Controlled Trials as Topic | 2007 |
Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
Topics: Aged; Blood Chemical Analysis; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Hyperparathyroidism; Middle Aged; Osteoclasts; Radionuclide Imaging; Urine | 1984 |
[Diphosphonates in the treatment of hypercalcemia].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyroidism; Pamidronate | 1984 |
Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Male; Middle Aged; Paraplegia; Pilot Projects | 1980 |
Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Diarrhea; Diphosphonates; Drug Administration Schedule; Female; Humans; Hydroxyproline; Hypercalcemia; Hypocalcemia; Kidney Tubules; Male; Middle Aged; Necrosis | 1981 |
Use of dichloromethylene diphosphonate in metastatic bone disease.
Topics: Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Female; Humans | 1981 |
[Multifocal sarcoma associated with Paget's disease of bone. Effects of dichloromethylene diphosphate (author's transl)].
Topics: Aged; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Ilium; Male; Osteitis Deformans; Osteosarcoma; Ulna | 1981 |
Parenteral diphosphonates for treating malignant hypercalcemia.
Topics: Aged; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Hypercalcemia; Infusions, Parenteral; Male; Middle Aged; Time Factors | 1981 |
[Diphosphonates in the treatment of bone metastases].
Topics: Animals; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Carcinoma 256, Walker; Clodronic Acid; Diphosphonates; Humans; Neoplasm Transplantation; Neoplasms, Experimental; Osteitis Deformans; Osteolysis; Rats | 1981 |
Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.
Topics: Adult; Aged; Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Female; Humans; Hypercalcemia; Injections, Intravenous; Male; Middle Aged | 1982 |
[Clodronate in treatment of tumor osteopathy. Evaluation in tumor patients with bone metastases or hypercalcemia].
Topics: Adult; Aged; Bone Neoplasms; Clodronic Acid; Female; Humans; Hypercalcemia; Male; Middle Aged; Pain Measurement; Palliative Care; Paraneoplastic Syndromes; Quality of Life | 1994 |
The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Clodronic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hydroxyproline; Infusions, Intravenous; Male; Middle Aged; Pain Measurement; Palliative Care; Prostatic Neoplasms | 1994 |
Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Drug Resistance; Humans; Infusions, Intravenous; Male; Pain; Pain Measurement; Palliative Care; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 1995 |
The bisphosphonate dilemma.
Topics: Alendronate; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; False Negative Reactions; Female; Humans; Hypercalcemia; Middle Aged; Parathyroid Neoplasms; Radionuclide Imaging; Technetium Tc 99m Medronate | 1995 |
The use of bisphosphonates in prostatic cancer.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Male; Prostatic Neoplasms | 1994 |
A new schedule for clodronate treatment in patients with breast cancer and bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Infusions, Intravenous; Middle Aged | 1993 |
Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer.
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; False Negative Reactions; Female; Humans; Middle Aged; Prospective Studies; Radionuclide Imaging; Sensitivity and Specificity; Technetium Tc 99m Medronate; Time Factors | 1993 |
Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP.
Topics: Animals; Bone Neoplasms; Carcinoma 256, Walker; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Drug Screening Assays, Antitumor; Hypercalcemia; Male; Osteolysis; Rats; Rats, Wistar; Tibia | 1993 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Hypercalcemia; Multiple Myeloma; Osteoporosis; Pain; Pamidronate | 1995 |
Bisphosphonates spearhead new approach to treating bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Growth Substances; Humans; Pamidronate; Quality of Life | 1997 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured | 1997 |
Prostate cancer and bone metastases. The effect of clodronate.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Development; Bone Neoplasms; Bone Resorption; Clodronic Acid; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1998 |
Bisphosphonates as anticancer drugs.
Topics: Apoptosis; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Neoplasm Metastasis; Osteoclasts | 1998 |
Minimizing breast cancer's spread.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans | 1998 |
Bisphosphonates: lingering questions about their use.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans | 1998 |
Clodronate in metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Humans; Neoplasm Metastasis; Prognosis | 1998 |
Clodronate in metastatic breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Humans; Neoplasm Metastasis | 1998 |
No value of oral clodronic acid in malignant osteolysis.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Double-Blind Method; Drug Evaluation; Humans; Pain; Palliative Care; Treatment Outcome | 1998 |
Clodronate in the management of bone metastases: a clinical study of 91 patients.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Female; Humans; Male; Middle Aged; Retrospective Studies | 1999 |
[Biosphonates in oncology].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Neoplasms; Osteolysis; Pain; Pamidronate; Spinal Cord Compression | 2000 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carrier Proteins; Cell Division; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glycoproteins; Growth Inhibitors; Membrane Glycoproteins; Osteoprotegerin; Osteosarcoma; Pamidronate; RANK Ligand; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tumor Cells, Cultured | 2001 |
Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Costs; Humans; Pain; Palliative Care; Pamidronate; Practice Patterns, Physicians'; Surveys and Questionnaires; United Kingdom | 2001 |
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Division; Clodronic Acid; Diphosphonates; DNA Fragmentation; DNA, Neoplasm; Humans; Osteosarcoma; Pamidronate; Phosphatidylserines; Tumor Cells, Cultured | 2001 |
Bisphosphonates may be useful in treatment of bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Male; Pamidronate; Prostatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
Reduction of visible bone metastases by clodronate therapy in breast cancer.
Topics: Analgesics, Non-Narcotic; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Clodronic Acid; Female; Humans; Middle Aged; Radionuclide Imaging; Treatment Outcome | 2001 |
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Topics: Alendronate; Antimetabolites; Bone Neoplasms; Cell Movement; Clodronic Acid; Dose-Response Relationship, Drug; Humans; Male; Mevalonic Acid; Neoplasm Invasiveness; Prostatic Neoplasms; Tumor Cells, Cultured | 2002 |
[Is pamidronate or clodronate better?].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Pamidronate | 2002 |
Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates.
Topics: Animals; Bone Neoplasms; Clodronic Acid; Diphosphonates; Male; Pamidronate; Prostatic Neoplasms; Rats; Time Factors; Tumor Cells, Cultured | 1992 |
Clodronate: the potential for the future.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Breast Neoplasms; Calcitonin; Clodronic Acid; Forecasting; Humans; Incidence; Osteolysis; Palliative Care; Survival Rate | 1991 |
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1991 |
[Value of Clodronate in the treatment of bone metastasis].
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Hypercalcemia; Male; Osteolysis; Prostatic Neoplasms | 1991 |
[Current possibilities in the therapy and prevention of bone metastases in breast carcinoma?].
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Etidronic Acid; Female; Humans | 1991 |
[Drug therapy with disodium clodronate combined with radiotherapy of bone metastasis of solid tumors].
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Clodronic Acid; Combined Modality Therapy; Female; Humans; Male; Middle Aged | 1990 |
[Role and use of biphosphonates in the treatment of metastatic breast cancer].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Hypercalcemia; Organophosphonates; Osteolysis | 1990 |
Disodium clodronate in the treatment of pain due to bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Clodronic Acid; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pain, Intractable | 1990 |
Pharmacokinetics of clodronate in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Blood Proteins; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Feces; Female; Humans; Injections, Intravenous; Middle Aged; Protein Binding; Saliva | 1989 |
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Calcium; Carcinoma; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1985 |
Clodronate--a new perspective in the treatment of neoplastic bone disease. Proceedings of a meeting. Helsinki.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans | 1987 |
New inhibitors of osteolysis: implications for hypercalcemia and bone metastases.
Topics: Amifostine; Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Osteolysis; Pamidronate; Plicamycin | 1986 |
Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP).
Topics: Adult; Aged; Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Drug Evaluation; Female; Humans; Hydroxyproline; Hypercalcemia; Male; Middle Aged; Neoplasms; Time Factors | 1985 |
Treatment of malignant hypercalcaemia with clodronate.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Calcium; Clodronic Acid; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Osteolysis | 1985 |
Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption.
Topics: Aged; Bone Neoplasms; Bone Resorption; Clodronic Acid; Drug Therapy, Combination; Humans; Male; Osteitis Deformans; Paralysis; Plicamycin; Prostatic Neoplasms | 1985 |